INTRODUCTION {#sec1}
============

Esophagectomy is the cornerstone for curative treatment of esophageal cancer. Open esophagectomy is increasingly being replaced by minimally invasive esophagectomy (MIE). Currently it is estimated that nearly 45% of patients are operated using a minimally invasive approach worldwide.[@ref1] MIE can be performed by hybrid minimally invasive esophagectomy (HMIE, laparotomy and thoracoscopy or laparoscopy and thoracotomy) or totally minimally invasive esophagectomy (TMIE, laparoscopy and thoracoscopy). In the Western world, laparoscopy-assisted HMIE is increasingly replaced by TMIE, in an attempt to further decrease postoperative morbidity without compromising patients' safety.[@ref1]

Systematic reviews of retrospective studies comparing the results of open esophagectomy to TMIE and open esophagectomy to HMIE have found that both HMIE and TMIE have advantages over the open approach in terms of blood loss, length of stay, and pulmonary complications.[@ref2]^,^[@ref3] In addition, these positive effects of MIE have been shown in a randomized controlled trial for HMIE[@ref4] and for TMIE.[@ref5] Because these beneficial effects seem to be comparable between HMIE and TMIE in these randomized controlled trials, HMIE and TMIE are currently considered to be surgical techniques with equivalently beneficial outcomes. However, no randomized controlled trials have compared HMIE and TMIE and no meta-analysis comparing HMIE and TMIE have been performed.

Therefore, the aim of this article was to perform a systematic review and meta-analysis of studies comparing HMIE with TMIE in patients undergoing esophagectomy.

MATERIALS AND METHODS {#sec2}
=====================

Literature search {#sec3}
-----------------

The review protocol is registered in the PROSPERO international prospective register of systematic reviews (number CRD 42016043291).[@ref6] PRISMA guidelines for systematic reviews were followed, and the PRISMA checklist is available in online Appendix I.[@ref7]

The electronic databases of MEDLINE, Embase, and the Cochrane central register of controlled trials were systematically searched. The search strategy was composed in collaboration with a medical librarian, and the exact (MEDLINE) search strategy was (minimal invasive\[tiab\] OR minimally invasive\[tiab\] OR laparo-thoracoscop^\*^\[tiab\] OR laparothoracoscop^\*^\[tiab\] OR thoracolaparoscop^\*^\[tiab\] OR thoraco-laparoscop^\*^\[tiab\] OR laparoscop^\*^\[tiab\] OR hybrid\[tiab\] OR VATS\[tiab\] OR video-assisted\[tiab\] OR video assisted\[tiab\] OR thoracoscop^\*^\[tiab\]) AND (esophagectom^\*^\[tiab\] OR oesophagectom^\*^\[tiab\] OR (resection^\*^\[tiab\] AND (oesophagus\[tiab\] OR oesophageal\[tiab\] OR oesophagal\[tiab\] OR esophagus\[tiab\] OR esophageal\[tiab\] OR esophagal\[tiab\]))). A cited reference search and hand search were additionally performed. No language restrictions were applied and all results up to April 2019 were included.

Criteria for selecting studies for this review {#sec4}
----------------------------------------------

Comparative cohort studies or randomized controlled trials comparing patients undergoing HMIE versus TMIE were included. We suspected that articles on 'outcome after MIE' could contain data on both HMIE and TMIE without this being explicitly described in the abstract. Therefore, we liberally included abstracts that contained outcome data after any form of MIE for full text screening.

Exclusion criteria were less than 10 patients per treatment arm and unclear description of operative technique rendering classification into HMIE or TMIE impossible. Studies that incorporated results of a transhiatal approach in the TMIE group were also excluded, because transhiatal resection cannot be performed as a hybrid procedure and inclusion would therefore be a source of selection bias. Video-assisted thoracic surgery (VATS) procedures and hand-assisted laparoscopic surgery (HALS) procedures were classified as minimally invasive and were also included.

Articles were selected for inclusion using a three-step review process. First, the titles and abstracts of all identified studies were examined by three reviewers (FvW, BK, and NB) independently, and studies that failed to meet the inclusion criteria were excluded. Second, reviewers (FvW, BK, and NB) independently examined the full text of potentially relevant articles. In the event of disagreement regarding the eligibility of a study during this phase, the opinion of a fourth reviewer (CR) was sought, and the parameters of the study's inclusion were discussed until consensus was reached. Third, all articles cited in and cited by the remaining eligible and relevant articles were independently assessed for inclusion.

Quality assessment {#sec5}
------------------

The Newcastle--Ottawa quality assessment scale was used to assess bias in studies included in this review.[@ref8] This scale rates studies on three sources of bias based on eight criteria. Each criterion is worth one star except confounding, which is worth two stars. For this systematic review, studies scoring seven to nine stars were considered to be of high methodological quality, studies scoring four to six stars were considered to be of moderate methodological quality, and studies scoring one to three stars were considered to be of low methodological quality.

Outcome parameters and data extraction {#sec6}
--------------------------------------

The primary outcome parameter was pneumonia. Secondary outcome parameters were all complications, severe complications (Clavien--Dindo\>2),[@ref9] pulmonary complications, anastomotic leakage, chyle leakage, RLN palsy, wound infection, reoperation, hospital length of stay, ICU length of stay, postoperative mortality, operating time, blood loss, R0 resection rate, number of lymph nodes, and quality of life. Data was extracted and was entered into Review Manager (version 5.3).

In case continuous variables were expressed as median and interquartile range or range, the mean and SD were estimated from the available data by methods described elsewhere.[@ref10]^,^[@ref11]

![Summary of screening and selection process---PRISMA diagram.](doaa021f1){#f1}

Analysis {#sec7}
--------

Since studies were homogeneous enough to pool, meta-analyses were performed, and statistical heterogeneity was assessed. The Mantel--Haenszel method was used for dichotomous data, presented as relative risks (RR) with 95% confidence intervals (CIs). The inverse variance method was used for meta-analysis of continuous data; results are presented as standardized mean difference (SMD) with 95% CIs. A random effects model was used for all analyses. The statistical heterogeneity was assessed with *I*^2^. A funnel plot with the effect measures on the *x*-axis and standard error of the log for the effect measures on the *y*-axis was created for the primary outcome parameter in order to assess publication bias.

In addition to comparing all articles reporting on outcome of patients undergoing HMIE versus TMIE, subgroup and sensitivity analyses were performed for (i) laparoscopy-assisted HMIE (minimally invasive abdominal phase and open thoracic phase) versus TMIE; (ii) thoracoscopy-assisted HMIE (minimally invasive thoracic phase and open abdominal phase) versus TMIE; (iii) Ivor Lewis HMIE versus Ivor Lewis TMIE; and (iv) McKeown HMIE versus McKeown TMIE. For the Ivor Lewis HMIE group, we decided to only include the Ivor Lewis laparoscopy-assisted HMIE (therefore excluding one study that compared Ivor Lewis thoracoscopy-assisted HMIE with Ivor Lewis TMIE), since this reflects the predominant change of practice that is currently taking place in the Western world.

RESULTS {#sec8}
=======

Studies {#sec9}
-------

Twenty-nine studies, including a total of 3,732 patients, met the inclusion criteria of this systematic review.[@ref12] A summary of the screening and selection process is shown in [Figure 1](#f1){ref-type="fig"}. The individual studies included 29--445 patients. In 14 studies (*n* = 1,631) laparoscopy-assisted HMIE was compared to TMIE; in 12 (*n* = 1,522) studies, thoracoscopy-assisted HMIE was compared to TMIE and 3 studies (*n* = 579) included both laparoscopy-assisted HMIE and thoracoscopy-assisted HMIE in the HMIE arm. Seven studies (*n* = 723) compared Ivor Lewis laparoscopy-assisted HMIE with Ivor Lewis TMIE, 15 studies (*n* = 2142) compared McKeown HMIE versus McKeown TMIE, and 7 studies (*n* = 867) used different or multiple surgical techniques of HMIE or TMIE and were therefore ineligible for subgroup analysis. These and other characteristics of the included studies are summarized in [Table 1](#TB1){ref-type="table"}.

###### 

Characteristics of included studies

  Study             Study design                 N     Type of HMIO                              Type of TMIO                           Surgery type HMIO                      Surgery type TMIO                      Outcome parameters
  ----------------- ---------------------------- ----- ----------------------------------------- -------------------------------------- -------------------------------------- -------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Berlth 2018       Retrospective cohort         60    LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis                             Pneumonia, pulm complications, AL, severe compl, all compl, RLN palsy, mortality, R0, WI, ICU LOS, hosp LOS, LN, OT, blood loss
  Bizekis 2006      Retrospective cohort         50    LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis                             Pneumonia, pulm compl, AL, chyle leak, mortality
  Blazeby 2011      Prospective cohort           124   LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis & McKeown                   Severe compl, reoperation, mortality, hosp LOS, LN, OT, blood loss
  Bonavina 2016     Retrospective cohort, PSMA   160   LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             McKeown                                Severe compl, pulm compl, AL, reoperation, chyle leak, RLN palsy, mortality, R0, WI, ICU LOS, hosp LOS, LN, OT, blood loss
  Daiko 2015        Cohort (not specified)       64    TA; thoracoscopy                          Laparoscopy and thoracoscopy           McKeown                                McKeown                                All compl, pneumonia, pulm compl, AL, chyle leak, RLN palsy, mortality, R0, WI, hospital LOS, LN, OT, blood loss.
  Elshaer 2017      Prospective cohort           26    LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis                             AL, chyle leak, mortality, hosp LOS, LN, OT.
  Findlay 2017      Prospective cohort           162   LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             McKeown                                AL, mortality, hosp LOS, LN.
  Fumagalli 2019    Prospective cohort           349   LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis                             AL.
  Grimminger 2018   Prospective cohort           50    LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis                             Pneumonia, AL, reoperation, chyle leakage, mortality, R0, WI, ICU LOS, hosp LOS, LN, OT
  Hamouda 2010      Prospective cohort           51    LA; laparoscopy                           Laparoscopy and VATS                   Ivor Lewis                             Ivor Lewis                             Pulm compl, AL, reoperation, chyle leak, R0
  Ichikawa 2013     Prospective cohort           315   TA; thoracoscopy                          HALS and thoracoscopy                  McKeown                                McKeown                                All compl, pulm compl, AL, chyle leak, RLN palsy, mortality, R0, ICU LOS, LN, OT, blood loss
  Kinjo 2012        Cohort (not specified)       106   TA; thoracoscopy                          HALS or laparoscopy and thoracoscopy   McKeown                                McKeown                                All compl, pneumonia, pulm compl, AL, reoperation, chyle leak, RLN palsy, mortality, R0, WI, ICU LOS, hosp LOS, blood loss
  Kitagawa 2016     Retrospective cohort         105   LA, laparoscopy                           Laparoscopy and thoracoscopy           McKeown                                McKeown                                Pneumonia, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, blood loss.
  Kubo 2014         Cohort (not specified)       135   LA; HALS                                  HALS and VATS                          McKeown                                McKeown                                All compl, pneumonia, pulm compl, AL, chyle leak, RLN palsy, mortality, ICU LOS, hosp LOS, OT, blood loss
  Lee 2011          Prospective cohort           74    TA; VATS                                  HALS and VATS                          McKeown                                McKeown                                Pulm compl, AL, mortality, ICU LOS, hosp LOS, LN, OT, blood loss
  Lee 2015          Cohort (not specified)       98    TA; VATS                                  Laparoscopy and VATS                   Ivor Lewis                             Ivor Lewis                             Pneumonia, pulm compl, AL, mortality, hosp LOS, LN, OT, blood loss
  Li 2018           Retrospective cohort         172   TA; thoracoscopy                          Laparoscopy and thoracoscopy           McKeown                                McKeown                                Pneumonia, pulm compl, AL, chyle leak, RLN palsy, WI, hosp LOS, LN, OT, blood loss
  Mao 2015          Retrospective cohort         59    LA and TA; laparoscopy and thoracoscopy   Laparoscopy and thoracoscopy           McKeown                                McKeown                                AL, mortality
  Martin 2005       Prospective cohort           36    TA; thoracoscopy                          HALS and thoracoscopy                  McKeown                                McKeown                                OT.
  Mu 2015           Retrospective cohort         445   LA and TA; laparoscopy & thoracoscopy     Laparoscopy and thoracoscopy           McKeown                                McKeown                                All compl, pulm compl, AL, mortality, R0, hosp LOS, LN, OT, blood loss
  Nilsson 2017      Cohort (not specified)       173   LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis and McKeown                 Pulm compl, AL, severe compl
  Nozaki 2017       Prospective cohort           101   TA; thoracoscopy                          HALS/laparoscopy and thoracoscopy      Ivor Lewis and McKeown (94% McKeown)   Ivor Lewis and McKeown (94% McKeown)   Pneumonia, pulm compl, AL, RLN palsy, mortality, hosp LOS, LN, OT, blood loss
  Oshikiri 2016     Cohort (not specified)       64    TA, thoracoscopy                          HALS and thoracoscopy                  McKeown                                McKeown                                Pneumonia, AL, RLN palsy, mortality, hosp LOS, OT, blood loss
  Safranek 2010     Prospective cohort           75    LA & TA; laparoscopy and thoracoscopy     Laparoscopy and thoracoscopy           McKeown                                McKeown                                Pneumonia AL, reoperation, RLN palsy, mortality, R0, ICU LOS, hosp LOS, LN, OT
  Smithers 2007     Prospective cohort           332   TA; thoracoscopy                          Laparoscopy and thoracoscopy           McKeown                                McKeown                                All compl, pneumonia, pulm compl, AL, chyle leak, RLN palsy, mortality, R0, ICU LOS, hosp LOS, LN, OT, blood loss
  Souche 2019       Prospective cohort           137   LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis                             Pneurmonia, pulm compl, AL, severe compl, reoperation, all compl, RLN palsy, mortality, R0, WI, hosp LOS, LN, OT, blood loss
  Tsujimoto 2012    Retrospective cohort         49    LA; laparoscopy                           Laparoscopy and thoracoscopy           Ivor Lewis                             Ivor Lewis & McKeown                   All compl, pulm compl, AL, chyle leak, RLN palsy, mortality, WI, ICU LOS, hosp LOS, OT, blood loss
  Yanasoot 2017     Cohort (not specified)       29    TA; thoracoscopy                          Laparoscopy and thoracoscopy           McKeown                                McKeown                                Pneumonia, AL, RLN palsy, mortality, WI, ICU LOS, Hosp LOS, OT, blood loss
  Yao 2017          Prospective cohort           131   TA; thoracoscopy                          Laparoscopy and thoracoscopy           McKeown                                McKeown                                Pulm compl, AL, chyle leak, RLN palsy, mortality, R0, WI, hosp LOS, LN, OT, blood loss

TMIE, totally minimally invasive esophagectomy; HMIE, hybrid minimally invasive esophagectomy; LA, laparoscopy assisted (thus: minimally invasive abdominal and open thoracic stage); TA, thoracoscopy assisted (thus: minimally invasive thoracic and open abdominal stage); PSMA, propensity score matched analysis; VATS, video-assisted thoracic surgery; HALS, hand-assisted laparoscopic surgery; compl, complications; pulm compl, pulmonary complications; AL, anastomotic leakage; RLN, recurrent laryngeal nerve; R0, R0 resection rate; WI, wound infection; ICU, intensive care unit; LOS, length of stay; LN, lymph nodes examined; OT, operating time

Quality and publication bias assessment {#sec10}
---------------------------------------

There were no randomized controlled trials. Studies scored six to nine stars out of nine according to the Newcastle--Ottawa rating scale, corresponding to a moderate to low risk of bias for non-randomized studies. The results of the quality assessment of the included studies are shown in online Appendix II.

By observation of the funnel plot for the primary outcome parameter in the main analysis, we concluded that publication bias may have been present because there appears to be a gap in the lower left quadrant of the funnel plot. However, the limited number of studies (*n* = 15) that reported the primary outcome parameter limits reliability of the plot \[Online Appendix III\].

Meta-analysis of all included studies comparing all HMIE with TMIE {#sec11}
------------------------------------------------------------------

A total of 15 studies including 1,492 patients reported the incidence of the primary outcome parameter. The pooled incidence of pneumonia was 19.0% after HMIE and 9.8% after TMIE which was not significantly different between the groups (RR: 1.46, 95% CI: 0.97--2.20). In a post hoc sensitivity analysis in which we excluded studies that included patients with HALS or VATS, these results remained similar (RR: 1.26, 95% CI: 0.85--1.89). Compared to HMIE, TMIE was associated with a lower incidence of wound infections (RR: 1.81, 95% CI: 1.13--2.90) and less blood loss (SMD: 0.78, 95% CI: 0.34--1.22) but with a longer operative time (SMD: -0.33, 95% CI: −0.59----0.08) (Appendix IV-a). The other parameters were not statistically different between the groups ([Table 2](#TB2){ref-type="table"}).

###### 

All hybrid minimally invasive esophagectomy versus totally minimally invasive esophagectomy

                                      No of studies   No of patients        RR/SMD (95% CI)         *I* ^2^ (%)
  ---------------------------------- --------------- ---------------- ---------------------------- -------------
  **Pneumonia (RR)**                       15              1492            1.46 (0.97--2.20)            39
  **Pulmonary complications (RR)**         18              2653            1.24 (0.97--1.58)            31
  **Anastomotic leakage (RR)**             27              3572            0.94 (0.73--1.21)            32
  **Chyle leakage (RR)**                   13              1641            1.13 (0.62--2.04)             0
  **RLN palsy (RR)**                       16              2035            0.90 (0.65--1.25)            22
  **Wound infection (RR)**                 11              1003         ***1.81 (1.13--2.90)***          0
  **Severe complications (RR)**             5              654             0.95 (0.72--1.25)            24
  **All complications (RR)**                9              1643            1.10 (0.99--1.23)             0
  **Reoperation (RR)**                      7              703             0.86 (0.51--1.46)             0
  **Postoperative mortality (RR)**         24              2951            1.33 (0.73--2.41)             0
  **Irradical resection (RR)**             13              2066            1.22 (0.93--1.60)             0
  **Intensive care LOS (SMD)**             12              1490            0.19 (0.00--0.38)            59
  **Hospital LOS (SMD)**                   23              2699            0.19 (0.00--0.39)            79
  **Extracted lymph nodes (SMD)**          19              2630           −0.01 (−0.24--0.22)           85
  **Operating time (SMD)**                 23              2782        ***−0.33 (−0.59--−0.08)***       88
  **Blood loss (SMD)**                     71              2701         ***0.78 (0.34--1.22)***         96

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR \> 1 favors TMIE and RR \< 1 favors HMIE. For continuous parameters, SMD \>0 favors TMIE and SMD \<0 favors HMIE, except for the parameter 'Extracted lymph nodes', in which SMD \>0 favors HMIE and SMD \<0 favors TMIE

Subgroup analyses per HMIE type {#sec12}
-------------------------------

In the laparoscopy-assisted HMIE versus TMIE subgroup, the incidence of pneumonia was described by 6 studies which included 451 patients. The incidence of pneumonia was 17.1% after laparoscopy-assisted HMIE and 8.5% after TMIE (RR: 1.68, 95% CI: 1.03--3.37). In addition, TMIE was associated with less blood loss (SMD: 0.39, 95% CI: 0.07--0.72) but with longer operative times (SMD: −0.50, 95%CI: −0.74--−0.25) and less extracted lymph nodes (SMD 0.29, 95%CI: 0.29--0.49) ([Table 3](#TB3){ref-type="table"}) (Appendix IV-b).

###### 

Laparoscopy-assisted hybrid minimally invasive esophagectomy versus totally minimally invasive esophagectomy

                                      No of studies   No of patients        RR/SMD (95% CI)         *I* ^2^ (%)
  ---------------------------------- --------------- ---------------- ---------------------------- -------------
  **Pneumonia (RR)**                        6              451          ***1.86 (1.03--3.37)***          9
  **Pulmonary complications (RR)**          9              889             1.15 (0.78--1.71)            44
  **Anastomotic leakage (RR)**             14              1581            0.79 (0.57--1.11)            30
  **Chyle leakage (RR)**                    5              521             1.10 (0.48--2.53)             0
  **RLN palsy (RR)**                        6              646             0.68 (0.35--1.35)            23
  **Wound infection (RR)**                  5              501             1.69 (0.96--2.96)             0
  **Severe complications (RR)**             5              654             0.95 (0.72--1.25)            24
  **All complications (RR)**                4              381             1.00 (0.82--1.22)             0
  **Reoperation (RR)**                      5              522             0.79 (0.43--1.46)             0
  **Postoperative mortality (RR)**         12              1132            1.28 (0.61--2.67)             0
  **Irradical resection (RR)**              6              620             1.44 (0.91--2.29)             0
  **Intensive care LOS (SMD)**              7              633             0.28 (−0.06--0.61)           75
  **Hospital LOS (SMD)**                   12              1082            0.16 (−0.08--0.39)           69
  **Extracted lymph nodes (SMD)**          10              898          ***0.29 (0.10--0.49)***         47
  **Operating time (SMD)**                 11              920         ***−0.50 (−0.74--−0.25)***       65
  **Blood loss (SMD)**                      9              844          ***0.39 (0.07--0.72)***         79

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR \> 1 favors TMIE and RR \< 1 favors HMIE. For continuous parameters, SMD \>0 favors TMIE and SMD \<0 favors HMIE, except for the parameter 'Extracted lymph nodes', in which SMD \>0 favors HMIE and SMD \<0 favors TMIE

In the thoracoscopy-assisted HMIE versus TMIE subgroup, the incidence of pneumonia was reported by 8 studies which included 966 patients. The incidence of pneumonia did not differ between the groups (RR: 1.24, 95% CI: 0.66--2.34). The overall complication rate was lower after TMIE compared to thoracoscopy-assisted HMIE (RR: 1.16, 95% CI: 1.02--1.32), and there was less blood loss after TMIE compared to thoracoscopy-assisted HMIE (SMD 1.03, 95%CI: 0.31--1.75) ([Table 4](#TB4){ref-type="table"}) (Appendix IV-c).

###### 

Thoracoscopy-assisted hybrid minimally invasive esophagectomy versus totally minimally invasive esophagectomy

                                      No of studies   No of patients       RR/SMD (95% CI)       *I* ^2^ (%)
  ---------------------------------- --------------- ---------------- ------------------------- -------------
  **Pneumonia (RR)**                        8              966            1.24 (0.66--2.34)          57
  **Pulmonary complications (RR)**          8              1319           1.33 (0.95--1.86)          30
  **Anastomotic leakage (RR)**             10              1412           1.28 (0.81--2.03)          29
  **Chyle leakage (RR)**                    6              1120           1.16 (0.50--2.69)           0
  **RLN palsy (RR)**                        9              1314           1.16 (0.92--1.45)           0
  **Wound infection (RR)**                  5              502            2.13 (0.88--5.14)           0
  **Severe complications (RR)**             0               0                    N/A                 N/A
  **All complications (RR)**                4              817         ***1.16 (1.02--1.32)***        0
  **Reoperation (RR)**                      1              106           3.18 (0.56--18.14)          N/A
  **Postoperative mortality (RR)**          9              1240           1.34 (0.36--5.08)          12
  **Irradical resection (RR)**              5              926            0.90 (0.57--1.42)           0
  **Intensive care LOS (SMD)**              4              782            0.17 (0.00--0.34)           0
  **Hospital LOS (SMD)**                    9              1097          0.31 (−0.12--0.74)          88
  **Extracted lymph nodes (SMD)**           7              1212          −0.37 (−0.81--0.07)         91
  **Operating time (SMD)**                 10              1342          0.21 (−0.65--0.23)          91
  **Blood loss (SMD)**                     10              1412        ***1.03 (0.31--1.75)***       97

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR \> 1 favors TMIE and RR \< 1 favors HMIE. For continuous parameters, SMD \>0 favors TMIE and SMD \<0 favors HMIE, except for the parameter 'Extracted lymph nodes', in which SMD \>0 favors HMIE and SMD \<0 favors TMIE

Subgroup analyses per resection type {#sec13}
------------------------------------

In the Ivor Lewis HMIE versus TMIE subgroup, the incidence of pneumonia was described by four studies (*n* = 297) and was not statistically different between the groups (RR: 1.83, 95% CI: 0.71--4.71). Compared to Ivor Lewis HMIE, Ivor Lewis TMIE was associated with a lower incidence of wound infections (RR: 7.33, 95% CI: 1.39--38.61) and less blood loss (SMD: 0.66, 95% CI: 0.36--0.95), but with a longer operative time (SMD: −0.47, 95% CI: −0.72--−0.0.23). Anastomotic leakage was reported in seven studies (*n* = 723), and the pooled incidence was 10.0% after Ivor Lewis HMIE compared to 18.9% after Ivor Lewis TMIE (RR: 0.55, 95% CI: 0.38--0.80) ([Table 5](#TB5){ref-type="table"}) (Appendix IV-d).

###### 

Laparoscopy-assisted hybrid minimally invasive Ivor Lewis esophagectomy versus totally minimally invasive Ivor Lewis esophagectomy

                                      No of studies   No of patients         RR/SMD (95% CI)          *I* ^2^ (%)
  ---------------------------------- --------------- ---------------- ------------------------------ -------------
  **Pneumonia (RR)**                        4              297              1.83 (0.71--4.71)             32
  **Pulmonary complications (RR)**          4              298              1.45 (0.98--2.15)              4
  **Anastomotic leakage (RR)**              7              723           ***0.55 (0.38--0.80)***           0
  **Chyle leakage (RR)**                    4              177              1.05 (0.21--5.28)              0
  **RLN palsy (RR)**                        2              197              4.18 (0.52--33.57)             0
  **Wound infection (RR)**                  2              187           ***7.33 (1.39--38.61)***          0
  **Severe complications (RR)**             2              197              0.85 (0.57--1.27)              0
  **All complications (RR)**                2              197              1.02 (0.79--1.32)              0
  **Reoperation (RR)**                      3              238              2.21 (0.44--11.06              0
  **Postoperative mortality (RR)**          5              323              0.85 (0.17--4.19)              0
  **Irradical resection (RR)**              4              298              1.63 (0.39--6.73)              0
  **Intensive care LOS (SMD)**              2              110              0.45 (−0.77--1.67)            89
  **Hospital LOS (SMD)**                    4              273             −0.05 (−0.31--0.21)             9
  **Extracted lymph nodes (SMD)**           4              273              0.17 (−0.09--0.42)             6
  **Operating time (SMD)**                  4              273         ***−0.47 (−0.72*--*-0.23)***        0
  **Blood loss (SMD)**                      2              197            ***0.66 (0.36--0.95***           0

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR \> 1 favors TMIE and RR \< 1 favors HMIE. For continuous parameters, SMD \>0 favors TMIE and SMD \<0 favors HMIE, except for the parameter 'Extracted lymph nodes', in which SMD \>0 favors HMIE and SMD \<0 favors TMIE

In the McKeown HMIE versus McKeown TMIE subgroup, the incidence of pneumonia was reported by 8 studies which included 947 patients. The incidence of pneumonia did not differ between the groups (RR: 1.45, 95% CI: 0.84--2.54). Compared to McKeown HMIE, McKeown TMIE was associated with a lower incidence of pulmonary complications (RR: 1.45, 95% CI: 1.05--1.99), less blood loss (SMD: 1.11, 95% CI: 0.46--1.75), and a shorter hospital length of stay (SMD: 0.38, 95% CI: 0.09--0.66) ([Table 6](#TB6){ref-type="table"}) (Appendix IV-e).

###### 

Hybrid minimally invasive McKeown esophagectomy versus totally minimally invasive McKeown esophagectomy

                                      No of studies   No of patients       RR/SMD (95% CI)       *I* ^2^ (%)
  ---------------------------------- --------------- ---------------- ------------------------- -------------
  **Pneumonia (RR)**                        8              947            1.46 (0.84--2.54)          52
  **Pulmonary complications (RR)**          9              1774        ***1.45 (1.05--1.99)***       21
  **Anastomotic leakage (RR)**             14              2106           1.26 (0.93--1.72)          19
  **Chyle leakage (RR)**                    7              1255           1.14 (0.58--2.25)           0
  **RLN palsy (RR)**                       11              1528           0.82 (0.56--1.22)          36
  **Wound infection (RR)**                  6              607            1.65 (0.98--2.78)           0
  **Severe complications (RR)**             0               0                    N/A                 N/A
  **All complications (RR)**                6              1397           1.13 (1.00--1.27)           0
  **Reoperation (RR)**                      2              181            1.25 (0.25--6.28)          55
  **Postoperative mortality (RR)**         13              1934           1.74 (0.68--4.48)           0
  **Irradical resection (RR)**              7              1446           1.12 (0.81--1.57)           0
  **Intensive care LOS (SMD)**              8              1171          0.12 (−0.02--0.26)           7
  **Hospital LOS (SMD)**                   12              1732        ***0.38 (0.09--0.66)***       83
  **Extracted lymph nodes (SMD)**           9              1712          −0.18 (−0.46--0.10)         83
  **Operating time (SMD)**                 13              1977          −0.26 (−0.62--0.10)         91
  **Blood loss (SMD)**                     12              1972        ***1.11 (0.46--1.75)***       83

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR \> 1 favors TMIE and RR \< 1 favors HMIE. For continuous parameters, SMD \>0 favors TMIE and SMD \<0 favors HMIE, except for the parameter 'Extracted lymph nodes', in which SMD \>0 favors HMIE and SMD \<0 favors TMIE

DISCUSSION {#sec14}
==========

This meta-analysis showed that a clinically relevant difference in the incidence of pneumonia between HMIE and TMIE might exist, but we were unable to demonstrate this since this difference did not reach statistical significance. Interestingly, in the subgroup analysis in which different types of HMIE were compared to TMIE, the incidence of pneumonia was lower after TMIE when it was compared with laparoscopy-assisted HMIE but not when it was compared with thoracoscopy-assisted HMIE. Although laparoscopy-assisted HMIE has clearly been shown to reduce pulmonary complications,[@ref4] this finding may implicate that a further reduction of postoperative pneumonia is possible by moving from laparoscopy-assisted HMIE to TMIE. In general, parameters regarding postoperative morbidity showed moderately improved outcome after TMIE compared to HMIE. However, we additionally found that anastomotic leakage was higher after Ivor Lewis TMIE compared to Ivor Lewis HMIE and that laparoscopy-assisted HMIE was associated with higher numbers of extracted lymph nodes compared to TMIE, and this suggests that TMIE can also have disadvantages regarding clinically important outcome parameters.

The major strength of this systematic review and meta- analysis is that this is the first study that directly compares the effectiveness of HMIE with TMIE. Some possible limitations should also be discussed. First, although statistical heterogeneity was limited, supporting our decision to pool results of the included studies in a meta-analysis, clinical heterogeneity (i.e. variations in surgical technique of HMIE and TMIE) was present. The variations in surgical technique of the included studies reflect the current lack of robust evidence on the optimal surgical technique for resection of esophageal cancer.[@ref1] In order to address this, we performed subgroup-and sensitivity analyses for which we included studies that only compared similar types of surgery, and this indeed resulted in lower heterogeneity for most parameters. Additionally, there was heterogeneity in our primary outcome parameter definition across studies. Second, selection bias could not be excluded since TMIE was most frequently implemented after HMIE and compared retrospectively, possibly favoring outcome in the TMIE group. However, the fact that the anastomotic leakage rate was higher after TMIE cannot be explained by this type of selection bias since TMIE cases were generally operated on in later time frames. In addition, TMIE has been described to be associated with a significant learning curve, and this might favor outcome in the HMIE group.[@ref41] Finally, the Newcastle--Ottawa rating scale was used because high-quality randomized studies were absent. Although this score gives a relevant indication of the quality of non-randomized studies, it generally results in an overestimation of the quality of the included studies, and this should be taken into account when interpreting the results of this study.

Currently, no RCTs have been performed that compared the effectiveness of HMIE versus TMIE, and as far as we are aware, no RCTs are currently being performed on this subject. Although the ROMIO feasibility trial has randomized between open, laparoscopy-assisted HMIE and TMIE, this feasibility study was not designed to identify a difference between HMIE and TMIE,[@ref45] and the definitive ROMIO trial does not randomize patients between open esophagectomy and laparoscopy-assisted HMIE.[@ref46] Therefore, surgeons will have to rely on non-randomized data when making decisions regarding whether to use HMIE or TMIE for surgical resection of esophageal cancer. The current meta-analysis provides an overview of the best available evidence on differences in outcome of HMIE compared to TMIE. From our data, TMIE was generally associated with a (trend towards) lower postoperative morbidity compared to HMIE. This suggests that TMIE has potential benefits over HMIE regarding morbidity. However, anastomotic leakage was higher after Ivor Lewis TMIE compared to Ivor Lewis HMIE. This may be explained by a surgical learning curve, which has been described to be long for Ivor Lewis TMIE (\>100 cases, which can correspond to years of practice),[@ref41]^,^[@ref43]^,^[@ref44] since intrathoracic anastomosis can be difficult to perform safely with minimally invasive techniques. Although no studies have been published that directly compare learning curves of HMIE and TMIE, it is assumed that HMIE is associated with a shorter learning curve and less associated morbidity because it is technically less complex. However, literature also shows that favorable results of TMIE can be achieved after the learning curve has been completed,[@ref43]^,^[@ref44] but this might not have been the case in most included studies. Another important finding is that laparoscopy-assisted HMIE was associated with higher numbers of extracted lymph nodes compared to TMIE. This suggests that surgeons performing thoracoscopic instead of open thoracic resection performed a more limited lymph node dissection, although other factors (e.g. pathology department related) may have also influenced lymph node count. In general, higher lymph node count is associated with improved survival after esophagectomy, and this is therefore an important finding.[@ref47] However, similar rates of extracted lymph nodes after minimally invasive versus open surgery and even higher numbers of extracted lymph nodes after thoracoscopic versus open transthoracic resection have been reported.[@ref48]^,^[@ref49]

![All hybrid minimally invasive esophagectomy (HMIE) versus totally minimally invasive esophagectomy (TMIE) for primary outcome parameter pneumonia.](doaa021f2){#f2}

Clinical implications {#sec15}
---------------------

Currently, HMIE and TMIE are regarded as equally effective, and safe surgical approaches and both procedures are used to treat patients with esophageal cancer worldwide. In this meta-analysis, a moderate benefit for TMIE regarding morbidity was found. Because outcomes between HMIE and TMIE are only moderately different, the learning curve of HMIE and TMIE procedures and its associated morbidity may also be important arguments in choosing which type of procedure to implement.[@ref50] Therefore, surgeons moving from HMIE to TMIE should carefully consider this, since this study showed that TMIE can also have disadvantageous effects and randomized controlled evidence supporting the benefits of TMIE over HMIE is lacking.

CONCLUSIONS {#sec16}
===========

In general, TMIE was associated with moderately lower morbidity compared to HMIE, but randomized controlled evidence is lacking. The higher leakage rate and lower lymph node count that was found after TMIE in sensitivity analysis indicate that TMIE can also have disadvantages. The findings of this meta-analysis should be considered carefully by surgeons when moving from HMIE to TMIE.
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APPENDIX I---PRISMA checklist
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1\. *From:* Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:[10.1371/journal.pmed1000097](10.1371/journal.pmed1000097)
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Appendix IV-a: Main analysis including all HMIE versus all TMIE {#sec18}
===============================================================

1.  *Wound infection*

Relative risk (RR) \> 1 favors TMIE and RR \< 1 favors HMIE.

1.  *Operating time*

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE

1.  *Blood loss*

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE.

Appendix IV-b: Subgroup analysis including laparoscopy-assisted hybrid minimally invasive esophagectomy versus totally minimally invasive esophagectomy {#sec19}
=======================================================================================================================================================

1.  *Pneumonia*

Relative risk (RR) \> 1 favors TMIE and RR \< 1 favors HMIE.

1.  *Extracted lymph nodes*

Standardized mean difference (SMD) \>0 favors HMIE and SMD \<0 favors TMIE.

1.  Operative time

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE

1.  Blood loss

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE.

Appendix IV-c: Subgroup analysis including thoracoscopy-assisted hybrid minimally invasive esophagectomy versus totally minimally invasive esophagectomy {#sec20}
========================================================================================================================================================

1.  All complications

Relative risk (RR) \> 1 favors TMIE and RR \< 1 favors HMIE.

1.  Blood loss

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE.

Appendix IV-d: Subgroup analysis including laparoscopy-assisted hybrid minimally invasive Ivor Lewis esophagectomy versus totally minimally invasive Ivor Lewis esophagectomy {#sec21}
=============================================================================================================================================================================

1.  Anastomotic leakage

Relative risk (RR) \> 1 favors TMIE and RR \< 1 favors HMIE.

1.  Wound infection

Relative risk (RR) \> 1 favors TMIE and RR \< 1 favors HMIE.

1.  Operating time

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE

1.  Blood loss

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE.

Appendix IV-e: Subgroup analysis including hybrid minimally invasive McKeown esophagectomy versus totally minimally invasive McKeown esophagectomy {#sec22}
==================================================================================================================================================

1.  Pulmonary complications

Relative risk (RR) \> 1 favors TMIE and RR \< 1 favors HMIE.

1.  Hospital length of stay

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE

1.  Blood loss

Standardized mean difference (SMD) \>0 favors TMIE and SMD \<0 favors HMIE.
